AVIZOR, S.A. – Trademark Portfolio

Entity Type: 99

AVIZOR, S.A. holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 14 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 6 are pending. Notable registered marks include AVIZOR LACRIFRESH and AVIZOR ALL CLEAN SOFT. The owner is based in Madrid.

La Cañada, 17

Madrid 28850 , ES

14 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

AVIZOR, S.A.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (14 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does AVIZOR, S.A. have?

AVIZOR, S.A. has 14 U.S. trademarks filed with the USPTO. Of these, 2 registered, 6 pending, 5 abandoned.

What trademark classes does AVIZOR, S.A. file in?

AVIZOR, S.A. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are AVIZOR, S.A.'s most well-known trademarks?

AVIZOR, S.A.'s registered trademark portfolio includes well-known marks such as AVIZOR LACRIFRESH and AVIZOR ALL CLEAN SOFT. These are among 2 currently registered trademarks in the portfolio.

What is AVIZOR, S.A.'s trademark registration success rate?

AVIZOR, S.A. has a 29% trademark registration rate, with 2 out of 7 resolved applications resulting in successful registration. Currently, 6 applications are pending review.